Background

- Over 200 COVID-19 vaccines currently under development, including three in clinical trials in the United States.

- ACIP responding to ongoing pandemic and accelerated vaccine development through scheduling of monthly emergency ACIP meetings

- At the June 24th meeting, ACIP reviewed:
  - Overview of the COVID-19 Vaccine Work Group and terms of reference
  - SARS-CoV-2 disease, immunology, and epidemiology
  - COVID-19 vaccine development and the vaccine landscape
  - COVID-19 vaccine prioritization considerations
COVID-19 Work Group activities – July, 2020

- COVID-19 Vaccine Work Group meets weekly

- Topics covered in July:
  - Review of published phase I clinical trial results
  - Safety considerations for COVID-19 vaccines
  - Regulatory mechanisms for the deployment of COVID-19 vaccines
  - Epidemiology updates, including COVID-19 in healthcare personnel
  - COVID-19 vaccine prioritization considerations
  - Evidence to Recommendations framework to guide COVID-19 vaccine policy
Today’s agenda

- **Overview of COVID-19 vaccine clinical trials:** Dr. Julie Ledgerwood (NIAID)

- **COVID-19 vaccine safety considerations:** Dr. Kathryn Edwards (Vanderbilt University)

- **Considerations for FDA licensure vs. Emergency Use Authorization of COVID-19 vaccines:** Dr. Doran Fink (FDA)

- **Considerations for vaccine implementation:** Dr. Nancy Messonnier (CDC)

- **Epidemiology of COVID-19 in essential workers, including healthcare personnel:** Dr. Sara Oliver (CDC)

- **COVID-19 vaccine prioritization: work group considerations:** Dr. Sarah Mbaeyi (CDC)

- **Evidence to Recommendations framework and Work Group next steps:** Dr. Kathleen Dooling (CDC)
Considerations for prioritization of COVID-19 vaccines

- Work Group reviewing considerations for vaccine prioritization in specific groups using a phased approach:
  - Essential workers, including healthcare personnel
  - Persons at increased risk for severe COVID-19 disease (e.g., older adults, persons with underlying conditions, racial/ethnic minority groups)
  - General population

- Today’s session: Focus on essential workers, including healthcare personnel

- Review of prioritization considerations for other groups will be reviewed at upcoming ACIP meetings
“...a committee that will develop an overarching framework to assist policymakers in the U.S. and global health communities in planning for equitable allocation of vaccines against COVID-19”

Committee co-sponsored by NIH and CDC to inform the decisions by health authorities, including the ACIP:

- What criteria should be used in setting priorities for equitable allocation of vaccine?
- How should the criteria be applied in determining the first tier of vaccine recipients?
- How can countries ensure equity in allocation of COVID-19 vaccines?
- For the US, how can communities of color be assured access to vaccination?
- What steps should be taken to mitigate vaccine hesitancy, especially among high-priority populations?
Work group members

ACIP members
- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

Ex-officio/government members
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Eric Deussing
- CMS: Jeff Kelm
- BARDA: Christine Oshansky

CDC Co-leads
- Kathleen Dooling
- Sarah Mbaeyi

Liaisons
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

Liaisons, cont’d
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Althea House (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

Consultants
- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)
CDC participants

- Doug Campos-Outcalt
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Sam Graitcer
- Lisa Grohskopf
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui
- Cynthia Jorgensen
- Jessica MacNeil
- Rebecca Morgan
- Sara Oliver
- Anita Patel
- Stephanie Schrag
- Tom Shimabukuro
- Nathalie Thornburg
- Jennifer Verani
- Cindy Weinbaum
- Yon Yu
- Jane Zucker
Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.